After completing this CE program, the participant will understand the basic concepts of chemoprevention and will be able to discuss the currently existing clinical data for the chemoprevention of colorectal cancer.
Objectives
At the completion of this program the participant will be able to:
1. Discuss the complicating factors in performing chemoprevention trials.
2. Describe the dietary modifications to prevent colorectal cancer.
3. Describe the proposed mechanisms of action of agents used in the chemoprevention of colorectal cancer.
4. Discuss, and where appropriate recommend, appropriate agents for use in the chemoprevention of colorectal cancer.
5. Describe the differences between familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), and spontaneous adenoma formation.
BertramJ.S., KolonelL.N., MeyskensF.L.JrRationale and strategies for chemoprevention of cancer in humans [review]. Cancer Research.1987; 47: 3012–31.
6.
WattenbergL.W.Chemoprevention of cancer [review]. Cancer Research.1985; 45: 1–8.
7.
American Cancer Society.Cancer Facts and Figures–1999.Atlanta, GA: ACS; 1999, 1–36.
8.
HawkE., LubetR., LimburgP.Chemoprevention in hereditary colorectal cancer syndromes. Cancer.1999; 86.
9.
LynchP.M.Clinical challenges in management of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Cancer.1999; 86: 2533–9.
10.
SpornM.B., DunlopN.M., NewtonD.L.Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc.1976; 35: 1332–8.
11.
LippmanS.M., SpitzM.R.Cancer chemoprevention. Cancer Bulletin.1991; 43: 473–573.
12.
SpornM.B.Carcinogenesis and cancer: different perspectives on the same disease. Cancer Research.1991; 51: 6215–18.
13.
MoonR.C., MehtaR.G.Chemoprevention of experimental carcinogenesis in animals [review]. Prev Med.1989; 18: 576–91.
14.
LippmanS.M., LeeJ.S., LotanR.Biomarkers as intermediate end points in chemoprevention trials [review]. J Nat Cancer Institute.1990; 82: 55–60.
15.
BooneC.W., KelloffG.J., SteeleV.E.Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy [review]. Cancer Research.1992; 52: 1651–9.
16.
PitotH.C.The molecular biology of carcinogenesis [review]. Cancer.1993; 72: 962–70.
17.
ShieldsP.G., HarrisC.C.Molecular epidemiology and the genetics of environmental cancer [review]. JAMA.1991; 266: 681–7.
18.
ShieldsP.G., HarrisC.C.Principles of carcinogenesis: Chemical. In: DeVitaV.T.Jr., HellmanS., RosenbergS.A., eds. Cancer Principles and Practice of Oncology. Vol. 1. Philadelphia: J.B. Lippincott Co.; 1993, 200–12.
19.
LippmanS.M., BennerS.E., HongW.K.Chemoprevention: Strategies for the control of cancer [Review]. Cancer.1993; 72: 984–90.
20.
FearonE.R., VogelsteinB.A genetic model for colorectal tumorigenesis. Cell.1990; 61: 759–767.
21.
StarkG.R.DNA amplification in drug resistant cells and in tumors [review]. Cancer Surv.1986; 5: 1–23.
22.
GiardielloF.M.NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterology Clinics of North American.1996; 25: 349–61.
23.
WattenbergL.W.An overview of chemoprevention: Current status and future prospects. Proceedings of the Society for Experimental Biology and Medicine.1997; 216: 133–41.
24.
GarewalH.S., MeyskensF.L.JrChemoprevention of cancer. Hematology/Oncology Clinics of North America.1991; 5: 69–77.
25.
GreenwaldP., NixonD.W., MaloneW.F.Concepts in cancer chemoprevention research [review]. Cancer.1990; 65: 1483–90.
26.
KelloffG.J., MaloneW.F., BooneC.W.Progress in applied chemoprevention research [review]. Seminars in Oncology.1990; 17: 438–55.
27.
BooneC.W., KelloffG.J., MaloneW.E.Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review [review]. Cancer Research.1990; 50: 2–9.
28.
KelloffG.J., BooneC.W., CrowellJ.A.Chemopreventive drug development: perspectives and progress [review]. Cancer Epidemiol Biomarkers Prev.1994; 3: 85–98.
29.
SinghD.K., LippmanS.M.Cancer chemoprevention: Part 1. Retinoids and carotenoids and other classic antioxidants. Oncology.1998; 12: 1643–58.
30.
LangmanM., BoyleP.Chemoprevention of colorectal cancer. Gut.1998; 43: 578–85.
DorganJ.F., SchatzkinA.Antioxidant micronutrients in cancer prevention. Hematol Oncol Clin North Am.1991; 5: 43–68.
33.
SmalleyW., RayW.A., BaughertyJ.Use of nonsteroidal anti-inflammatory drugs and incidence of colon cancer. Arch Int Med.1999; 159: 161–6.
34.
RosenbergL., PalmerJr, ZauberA.G.A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Nat Cancer Institute.1991; 83: 355–8.
35.
ShiffS.J., RigasB.Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology.1997; 113: 1992–8.
36.
EarnestD.L., HixsonL.J., AlbertsD.S.Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention [review]. J Cell Biochem Suppl.1992; 161: 156–66.
37.
KuneS., KuneG.A., WatsonL.F.Case-control study of dietary etiological factors: The Melbourne Colorectal Cancer Study. Nutr Cancer.1987; 9: 21–42.
38.
LansJ.I., JaszewskiR., ArlowF.L.Supplemental calcium suppresses colonic mucosal ornithine decarboxylase activity in elderly patients with adenomatous polyps. Cancer Research.1991; 51: 3416–19.
39.
LotanR., NicolsonG.L.Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed, and tumor cells in vitro. J Nat Cancer Institute.1977; 59: 1717–22.
40.
BurningJ.E., HenneskensC.H.The possible role of beta-carotene in cancer prevention. Vol. 1989; July: 1–9.
41.
McBurneyM.W., CostaS., PrattM.A.C.Retinoids and cancer: A basis for differentiation therapy. Cancer Investigation.1993; 11: 590–8.
42.
GoodmanG.E.The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives [review]. Cancer Research.1992; 52: 2752s–7s.
43.
KelloffG.J., HawkE.T., CrowellJ.A.Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology.1996; 10: 1471–88.
44.
OliveriaS.A., ChristosP.J., BerwikM.The role of epidemiology in cancer prevention. Proceedings of the Society for Experimental Biology and Medicine.1997; 216: 142–50.
45.
KelloffG.J., BooneC.W., SteeleV.E.Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials [review]. Cancer Res.199454: 2015s–24s.
46.
SchatzkinA., SchiffmanM., LanzaE.Research priorities in large bowel cancer prevention [review]. Seminars in Oncology.1990; 17: 425–37.
47.
PillaiR., GarewalH.S., WoodS.Biological monitoring of cancer chemoprevention [review]. J Surg Oncol.1992; 51: 19–202.
48.
WillettW.C.Cancer prevention: Diet and risk reduction. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology. Vol. 1. Philadelphia: Lippincott-Raven; 1997, 559–66.
49.
GarayC.A., EngstromP.F.Chemoprevention of colorectal cancer: Dietary and pharmacologic approaches. Oncology.1999; 13: 89–98.
50.
FuchsC.S., GiovannucciE.L., ColditzG.A.Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med.1999; 340: 169–76.
51.
KuneG., KuneS., WatsonL.F.Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Research.1988; 48: 4399–404.
52.
WillettW.C., StampferM.J., ColditzG.A.Relationship of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med.1990; 323: 1664–72.
53.
GiovannucciE., StampferM.J., ColditzG.Relationship of diet to risk of colorectal adenoma in men. J Nat Cancer Institute.1992; 84: 91–8.
54.
McKeown-EyssenG.E., Bright-SeeE., BruceW.R.A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. J Clin Epidemiol.1994; 47: 525–36.
55.
SteinmetzK.A., KushiL.H., BostickR.M.Vegetables, fruit, and colon cancer in the Iowa women's health study. Am J Epidemiol.1994; 139: 1–15.
56.
MartínezM.E., McPhersonR.S., LevinB.A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps. Gastroenterol.1997; 113: 423–9.
57.
MacraeF.A., MacLennanR., WardM.A randomized controlled trial of fat, fibre, and beta carotene on colorectal adenomas. Gastroenterol.1995; 108: A501.
58.
MacLennanR., MacraeF., BainC.Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Nat Cancer Institute.1995; 87: 1760–6.
59.
La VaccinaC.Mediterranean epidemiological evidence on tomatoes and the prevention of digestive-tract cancers. Proceedings of the Society for Experimental Biology and Medicine.1998; 218: 125–8.
60.
KrimskyN.I.Overview of lycopene, carotenoids, and disease prevention. Proceedings of the Society for Experimental Biology and Medicine.1998; 218: 95–7.
61.
YamandaK., YoshidaK., SatoM.Proliferating cell nuclear antigen expression in normal, preneoplastic, and neoplastic colonic epithelium of the rat. Gastroenterol.1992; 103: 160–7.
62.
LipkinM.Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects [review]. Cancer Res.1988; 48: 235–45.
63.
BusetM., LipkinM., WinnowerS.Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. Cancer Res.1986; 46: 5426–30.
SlatteryM.L., SorensonA.W., FordM.H.Dietary calcium intake as a mitigating factor in colon cancer. Am J Epidemiol.1988; 128: 504–14.
66.
LipkinM., NewmarkH.Effect of added dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer. N Engl J Med.1985; 313: 1381–4.
67.
RozenP., FiremanZ., FineN.Oral calcium suppresses increased rectal epithelial proliferation of persons at risk of colorectal cancer. Gut.1989; 30: 650–5.
68.
LipkinM., FriedmanE., WinawerS.J.Colonic epithelial cell proliferation in responders and non responders to supplemental dietary calcium. Cancer Res.1989; 49: 248–54.
69.
GregorieR.C., SternH.S., YeungK.S.Effect of calcium supplementation on mucosal cell proliferation in high risk patients for colon cancer. Gut.1989; 30: 376–82.
70.
SternH.S., GregoireR.C., KashtanH., StadlerJ., BruceR.W.Long-term effects of dietary calcium on risk markers for colon cancer in patients with familial polyposis. Surgery.1990; 108: 528–33.
71.
WargovichM.J., IsbellG., ShabotM.Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. Gastroenterol.1992; 103: 92–7.
72.
AlbertsD., Rees-McGeeS., EinspahrJ.Double-blind, placebo controlled study of wheat bran fiber (WBF) vs calcium carbonate (CALC) in patients with resected adenomatous polyps. Proc Annu Meet Am Assoc Cancer Res.1992; 33: 207.
73.
BostickR.M., PotterJ.D., FosdickL.Calcium and colorectal epithelial cell proliferation: A preliminary randomized, double-blinded, placebo-controlled clinical trial. J Nat Cancer Institute.1993; 85: 132–41.
74.
BostickR.M., FosdickL., WoodJrCalcium and colorectal epithelial cell proliferation in sporadic adenoma patients: A randomized, double-blinded, placebo-controlled trial. J Nat Cancer Institute.1995; 87: 1307–15.
75.
CatsA., KleibeukerJ.H., van der MeerR.Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. J Nat Cancer Institute.1995; 87: 598–603.
76.
GreenwaldP.Cancer prevention: Diet and risk reduction. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology. Vol. 1. Philadelphia: Lippincott-Raven; 1997: 566–73.
WaddellW.R., LoughrR.W.Sulindac for polyposis of the colon. J Surgical Oncol.1983; 24: 83–7.
79.
WaddellW.R., GanserG.F., CeriseE.J.Sulindac for polyposis of the colon. Am J Surg.1989; 157: 175–9.
80.
ThunM.J., NamboodiriM.M., HeathC.W.JrAspirin use and reduced risk of fatal colon cancer. N Engl J Med.1991; 325: 1593–6.
81.
RigauJ., PiqueJ.M., RubioE.Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med.1991; 115: 952–4.
82.
Paganini-HillA., HsuG., RossR.K.Aspirin use and reduced risk of fatal colon cancer. N Engl J Med.1992; 326: 1290–1.
83.
JalbertG., CastonguayA.Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett.1992; 66: 21–8.
84.
LeeI-M, HennekensC.H., BurningJ.E.Use of aspirin and other nonsteroidal antiinflammatory drugs and the risk of cancer development. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology. Vol. 1. Philadelphia: Lippincott-Raven; 1997, 599–607.
85.
AhnenD.J.Colon cancer prevention by NSAIDs: What is the mechanism of action?European J Surg.1998; 164: 111–4.
86.
VainioH., MorganG.Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scandinavian J Gastroenterol.1998; 33: 785–9.
87.
LabayleD., FischerD., VielhP.Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterol.1991; 101: 635–9.
88.
GiardielloF.M., HamiltonS.R., KrushA.Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. J Nat Cancer Institute.1993; 328: 1313–6.
89.
WindeG., SchmidK.W., BrandtB.Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Diseases of the Colon and Rectum.1997; 40: 1156–69.
90.
NugentK.P., FarmerK.C.R., SpiglemanA.D.Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. British J Surg.1993; 80: 1618–9.
91.
DiSarioJ., AlbertsD., TietzeC.Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastroenterol.1997; 112: A555.
92.
GiovannucciE., RimmE.B., StampferM.J.Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Int Med.1994; 121: 241–6.
93.
KrishananK., RuffinM.T., BrennerD.E.Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. J Cellular Biochem.1997: 148–58.
94.
HennekensC.H.Issues in the design and conduct of clinical trials. J Nat Cancer Institute.1984; 73: 1473–6.
95.
GannP.H., MansonJoe, GlynnR.J.Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Nat Cancer Institute.1993; 85: 1220–4.
96.
Steering Committee of the Physicians' Health Study Research Group.Final report on aspirin component of the ongoing Physicians' Health Study. N Engl J Med.1989; 321: 129–35.
97.
StürmerT., GlynnR.J., LeeI-M, MansonJ.E.Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study. Ann Int Med.1998; 128: 713–20.
98.
GiovannucciE., EganK.M., HunterD.J.Aspirin and the risk of colorectal cancer in women. N Eng J Med.1995; 333: 609–14.
99.
SandlerR.S., GalankoJ.C., HelmJ.F.Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterol.1998; 114: 441–7.
100.
DannenbergA.J., ZakimD.Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Sem Oncol.1999; 26: 499–504.]
101.
HongW.K., SpornM.B.Recent advances in chemoprevention of cancer. Science.1997; 278: 1073–7.
102.
CrewT.E., ElderD.J.E., ParaskevaC.A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis.2000; 21: 69–77.
103.
SubbaramaiahK., ZakimD., WekslerB.B.Inhibition of cyclooxygenase: A novel approach to cancer prevention. Proceedings of the Society for Experimental Biology and Medicine.1997; 216: 201–10.
104.
EberhartC.E., CoffeyR.J., RadhikaA.Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol.1997; 107: 1183–8.
105.
Celebrex package insert.Chicago, IL and New York, NY: Searle and Pfizer; 1999.
106.
SandlerR.S.Aspirin and other non-steroidal anti-inflammatory agents in the prevention of colorectal cancer. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Important Advances in Oncology.Philadelphia: Lippincott-Raven; 1996, 123–37.
107.
BusseyH.J.R.Jr., DeCosseJ., DeschnerE.E.A randomized trial of ascorbic acid in polyposis coli. Cancer.1982; 50: 1434–1439.
108.
McKeown-EyssenG., HollowayC., JazmajiV.A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Res.1988; 48: 4701–5.
109.
DeCosseJ.J., MillerH.H., LesserM.L.Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Nat Cancer Institute.1989; 81: 1290–7.
110.
PaganelliG.M., BiascoG., BrandiG.Effect of vitamin A, C, and E supplementation on rectal cell proliferation in patients with colorectal adenomas. J Nat Cancer Institute.1992; 84: 47–51.
111.
RoncucciL., Di DonatoP., CaratiL.Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Diseases of the Colon and Rectum.1993; 36: 227–34.
112.
GreenbergE.R., BaronJ.A., TostesonT.D.A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med.1994; 331: 141–7.
113.
Ponz de LeonM., RoncucciL.Chemoprevention of colorectal tumors: Role of lactulose and of other agents. Scandinavian J Gastroenterol.1997; 32: 72–5.
114.
CalleE.E., Miracle-McMahillH.L., ThunM.J.Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Nat Cancer Institute.1995; 87: 517–23.
115.
NewcombP.A., StorerB.E.Post-menopausal hormone use and risk of large-bowel cancer. J Nat Cancer Institute.1995; 87: 1067–71.
116.
TroisiR., SchairerC., ChowW-HA prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes and Control.1997; 8: 130–8.
117.
KampmanE., PotterJ.D., SlatteryM.L.Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes and Control.1997; 8: 146–58.
118.
GrodsteinF., MartinezE., PlatzE.A.Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Int Med.1998; 128: 705–12.
119.
LashnerB.Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol.1993; 119: 549–54.
120.
MasonJ.B., LevesqueT.Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology.1996; 10: 1727–43.
121.
SmithR.A., MettlinC.J., JohnstonK.J., EyreH.American Cancer Society guidelines for the early detection of cancer. CA: A Cancer Journal for Clinicians.2000; 50: 34–49.
122.
RosenblumD.S., ShiffS.J.Chemo-prevention of colorectal cancer: a practical approach. Primary Care and Cancer.1999; 19: 22–6.
123.
SinghD.K., LippmanS.M.Cancer chemoprevention: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Oncology.1998; 12: 1787–1800.
